The Cooper Companies stock (US2166481027): Drops 0.80% to $59.47

The Cooper Companies stock fell 0.80% on May 13, 2026, closing at $59.47 after trading at $59.95. Year-to-date, shares are down 27.4% from $81.96.

The Cooper Companies stock declined 0.80% on Wednesday, May 13, 2026, closing at $59.47 after opening near $59.95 on Nasdaq, according to stockinvest.us as of 05/13/2026. The shares have fallen 27.4% year-to-date from $81.96, reflecting broader pressures in the healthcare sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: The Cooper Companies, Inc.
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Contact lenses, intraocular lenses
• Home exchange/listing venue: Nasdaq (COO)
• Trading currency: USD

The Cooper Companies: core business model

The Cooper Companies designs, manufactures and markets medical devices, primarily in vision care and surgical procedures. Its CooperVision segment produces contact lenses, while CooperSurgical focuses on women's health and fertility solutions. The company generates revenue through global distribution to eye care professionals and healthcare providers, according to investor.coopercos.com as of 05/14/2026.

This dual-segment model provides diversification, with contact lenses driving recurring sales and surgical products offering higher margins. The firm serves over 100 countries, emphasizing innovation in daily disposable lenses and minimally invasive devices.

Main revenue and product drivers for The Cooper Companies

Contact lenses account for the majority of revenue, with products like Biofinity and MyDay targeting myopia management and daily wearers. CooperSurgical contributes through endometrial ablation systems and fertility diagnostics, supporting growth in reproductive health. In fiscal 2025 (ended Oct 31, 2025), the company reported net margins of 9.67%, outperforming peers, per MarketBeat as of 05/14/2026.

Key drivers include premium lens adoption in the US market and expansion in emerging regions. Return on equity stood at 10.34% for the period ended Oct 31, 2025, highlighting efficient capital use amid competitive pressures.

Industry trends and competitive position

The vision care market grows at 5-7% annually, driven by aging populations and digital eye strain in the US. The Cooper Companies competes with Alcon and Johnson & Johnson, holding a strong position in specialty lenses. Its net margin of 9.67% for fiscal 2025 exceeded Alcon's 7.70%, according to MarketBeat data as of 05/14/2026.

Why The Cooper Companies matters for US investors

Listed on Nasdaq, The Cooper Companies offers US investors exposure to stable healthcare demand, with over 50% of revenue from North America. Its focus on vision correction aligns with rising US myopia rates, providing a defensive play in medical devices.

Conclusion

The Cooper Companies stock recently declined 0.80% to $59.47 on May 13, 2026, amid a 27.4% year-to-date drop. The company maintains solid fundamentals in vision care and surgical devices, with strong margins for fiscal 2025. Investors track its position in growing US healthcare markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.